Stockscreener 앱 받기
8.36
1.99%
-0.17
시간 외 거래:
8.39
0.03
+0.36%
Fennec Pharmaceuticals Inc 주식(FENC)의 최신 뉴스
Fennec Pharmaceuticals Reports Strong Q2 2025 Results and Expands Global Reach - TipRanks
How to manage a losing position in Fennec Pharmaceuticals Inc.July 2025 Action & Risk Managed Trade Strategies - Newser
Fennec Pharmaceuticals 2025 Q2 Earnings Narrowing Losses with 43.2% Net Income Improvement - AInvest
Will Fennec Pharmaceuticals Inc. stock go up soonInsider Buying & Expert Verified Stock Movement Alerts - Newser
Measuring Fennec Pharmaceuticals Inc.’s beta against major indicesWall Street Watch & Fast Gaining Stock Strategy Reports - Newser
Fennec Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
How Fennec Pharmaceuticals Inc. stock performs during market volatilityJuly 2025 Movers & Verified Chart Pattern Trade Signals - Newser
Fennec Pharmaceuticals Q2 2025: Unpacking Key Contradictions in Patient Adherence, Production Timelines, and Market Strategies - AInvest
What data driven models say about Fennec Pharmaceuticals Inc.’s futureShare Buyback & Free Reliable Trade Execution Plans - Newser
Fennec Q2 Sales Jump 33 Percent - The Motley Fool
Transcript : Fennec Pharmaceuticals Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener
Earnings call transcript: Fennec Pharmaceuticals Q2 2025 results disappoint - Investing.com
Fennec Pharmaceuticals Q2 Net Loss Narrows as Revenue Advances - 富途牛牛
Fennec Pharmaceuticals Sees Strong Q2 Growth and Expands Global Reach - TipRanks
Fennec Pharmaceuticals reports second quarter 2025 financial results - MarketScreener
Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update - The Manila Times
Fennec Pharmaceuticals: Leveraging PEDMARK's Triple Drivers for Long-Term Value in a Niche Oncology Market - AInvest
Fennec Pharmaceuticals Q2 Revenue Beats Expectations, GAAP EPS Misses - AInvest
Applying chart zones and confluence areas to Fennec Pharmaceuticals Inc.Entry Point & High Return Stock Watch Alerts - Newser
Using data filters to optimize entry into Fennec Pharmaceuticals Inc.July 2025 Drop Watch & Weekly Setup with High ROI Potential - Newser
Why Fennec Pharmaceuticals Inc. is moving todayPortfolio Profit Report & AI Enhanced Trading Alerts - Newser
Can trapped investors hope for a rebound in Fennec Pharmaceuticals Inc.Weekly Stock Report & Community Consensus Stock Picks - Newser
How to interpret RSI for Fennec Pharmaceuticals Inc. stockWeekly Stock Recap & Weekly Setup with ROI Potential - Newser
Why Fennec Pharmaceuticals Inc. stock attracts strong analyst attention [2025 Historical Comparison]Community Trade Idea Sharing - Newser
Fennec Pharmaceuticals Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Fennec Pharmaceuticals FENC 2025Q2 Earnings Preview Downside Risk Amid Product Vulnerabilities - AInvest
Stocks In Play: Fennec Pharmaceuticals Inc. - Barchart.com
Fennec Pharmaceuticals to Announce Q2 2025 Financial Results - TipRanks
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025 - The Manila Times
Fennec Pharmaceuticals to announce Q2 2025 financial results on Aug. 14. - AInvest
Fennec Pharmaceuticals Sets Q2 Earnings Date: Specialty Pharma Company to Update Investors August 14 - Stock Titan
Fennec Pharmaceuticals Inc. stock outlook for YEAREarly Entry Ideas with Momentum Potential - Newser
Real time pattern detection on Fennec Pharmaceuticals Inc. stockDividend Strategy Summary With 10-Year Outlook - Newser
Adherex Technologies (FENC) to Release Earnings on Tuesday - Defense World
What makes Fennec Pharmaceuticals Inc. stock price move sharplyShort-Term Swing Opportunity Summary Sheet - Newser
Fennec Pharmaceuticals FENC Q2 2025 Earnings Preview Downside Concerns Amid Product Vulnerability Issues - AInvest
Full technical analysis of Fennec Pharmaceuticals Inc. stockPredictive Model for Intraday Swing Forecast - Newser
Anterix Holds Virtual Annual Stockholders Meeting - The Globe and Mail
Paymentus Holdings: Strong Growth and Raised Guidance - The Globe and Mail
Evaluating Fennec Pharmaceuticals Inc. with trendline analysisCapital Protection Strategy With Risk Analysis - Newser
0.41%
0.88%
자본화:
|
볼륨(24시간):